| 產(chǎn)品編號(hào) | bs-7362R-APC |
| 英文名稱(chēng)1 | Rabbit Anti-Melan A/APC Conjugated antibody |
| 中文名稱(chēng) | APC標(biāo)記的黑色素瘤相關(guān)抗原/黑色素-A抗體 |
| 別 名 | Protein Melan-A; Antigen LB39 AA; Melanoma HMB45; Antigen SK29 AA; Antigen SK29-AA; CMM 1; CMM; CMM1; Cutaneous Malignant Melanoma Dysplastic Nevus; DNS; Dysplastic Nevus Syndrome; FAMMM; MART1; melan A; Melan A protein; Melanoma antigen recognized by T-cells 1; MLM; Monophenol monooxygenase; Tumor rejection antigen AB; tyrosinase; Melanoma HMB45; Melanoma; Melan-A; MART-1; MAR1_HUMAN. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) t-淋巴細(xì)胞 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Mouse, Rat, ) |
| 產(chǎn)品應(yīng)用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 13kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from mouse Melan A |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Melanoma-associated antigens recognized by cytotoxic T lymphocytes (CTL) have been grouped into three categories: melanocyte differentiation antigens, cancer/testis-specific antigens and mutated or aberrantly expressed antigens. Many of these antigens consist of peptides that are presented to T cells by HLA molecules; they represent potential targets for cancer immunotherapy. Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients. Function: Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes. Subunit: Interacts with PMEL. Interacts with GPR143. Subcellular Location: Endoplasmic reticulum membrane. Golgi apparatus. Golgi apparatus > trans-Golgi network membrane. Melanosome. Also found in small vesicles and tubules dispersed over the entire cytoplasm. A small fraction of the protein is inserted into the membrane in an inverted orientation. Inversion of membrane topology results in the relocalization of the protein from a predominant Endoplasmic reticulum membrane. Golgi apparatus. Golgi apparatus > trans-Golgi network membrane. Melanosome. Also found in small vesicles and tubules dispersed over the entire cytoplasm. A small fraction of the protein is inserted into the membrane in an inverted orientation. Inversion of membrane topology results in the relocalization of the protein from a predominant Golgi/post-Golgi area to the endoplasmic reticulum. Melanoma cells expressing the protein with an inverted membrane topology are more effectively recognized by specific cytolytic T-lymphocytes than those expressing the protein in its native membrane orientation. Tissue Specificity: Expression is restricted to melanoma and melanocyte cell lines and retina. Post-translational modifications: Acylated. Database links: Entrez Gene: 77836 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
